#United States #Princeton #Soligenix #SGX945 #Behçet's Disease

Soligenix Advances SGX945 for Behçet's Disease Treatment

On February 26, 2026, Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company focused on addressing rare diseases with unmet medical needs, announced a significant achievement. The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has provided a positive opinion concerning the orphan drug designation request for SGX945, an investigational drug for Behçet's Disease. This recommendation comes after a comprehensive review of the promising Phase 2a clinical results, which showcased SGX945’s biological efficacy and safety in patients battling this challenging condition.

Understanding SGX945 and Its Development

SGX945 is built on the active pharmaceutical ingredient dusquetide, classified as an innate defense regulator (IDR). This new class of short, synthetic peptides aims to modulate the body's response to injury and infection, steering it towards an anti-inflammatory and tissue-repairing pathway. This mechanism is particularly crucial for addressing the complex symptoms associated with Behçet's Disease, an auto-immune condition yielding painful mouth sores, skin rashes, and other debilitating symptoms.

The necessity for effective treatment options is paramount. In the U.S. alone, approximately 18,000 individuals are estimated to be grappling with Behçet's Disease, with potentially up to 1 million affected globally. Current treatments often fall short in managing symptoms and can lead to significant side effects, highlighting the urgent need for innovative therapies like SGX945.

EMA's Orphan Drug Designation

The orphan drug designation from the EMA not only recognizes the critical need for effective therapies but also grants a 10-year market exclusivity following product approval in the European Union (EU). This status escalates the accessibility of resources including guidance from the EMA during the drug development process. The European Commission is expected to ratify the positive opinion, culminating in definitive orphan status which would aid in expediting SGX945’s path to market.

Clinical Trials and Results

In the recently concluded Phase 2a study, patients treated with SGX945 demonstrated a 40% improvement in the mean number of oral ulcers over placebo, a notable outcome given the disease's complexity. This improvement was maintained through an 8-week evaluation period, suggesting sustained efficacy post-treatment. The successful results in this pilot study bolster the hopes placed in SGX945, making it a potential game-changer for patients with Behçet's Disease, particularly those who have not responded adequately to existing options such as apremilast.

Looking Ahead

Dr. Christopher J. Schaber, the President and CEO of Soligenix, expressed enthusiasm over the EMA's positive opinion, emphasizing the company’s commitment to advancing this program. With no cure currently available for Behçet's Disease, the ongoing development of SGX945 embodies hope for many who endure the daily challenges posed by this serious condition.

The clinical landscape surrounding Behçet's is set to change, contingent upon the forthcoming regulatory approvals which will pave the way for SGX945’s introduction to the market. As Soligenix strives forward, they are also focusing on their other therapeutic programs, ensuring a robust pipeline aimed at enhancing treatment options for various rare diseases and conditions.

For further details about Soligenix and its innovative treatments, interested parties can visit Soligenix's website and follow their updates on LinkedIn and Twitter.